Injections that cause less pain and discomfort are more likely to be performed consistently, leading to better diabetes control
While both target GLP-1 receptors, Mounjaros dual agonism enhances efficacy, especially in obese and insulin-resistant populations
A key difference between these peptides is that while they both appear to increase the secretion and production of HGH in vitro and in vivo, only tesamorelin has undergone human clinical trials and has been approved by the FDA
On-Treatment Analysis (If Everyone Stayed on Max Dose): CagriSema achieved 22.7% weight loss using trial-product estimand (assumes perfect adherence at max dose)
Glucagon-like peptide 1 secretion by the L-cell
The combination of a valid US physician prescription, a licensed contracted pharmacy department, and direct home delivery removes many of the barriers that make consistent treatment difficult